Literature DB >> 8917734

Kinetics of retrovirus mediated gene transfer: the importance of intracellular half-life of retroviruses.

S T Andreadis1, B O Palsson.   

Abstract

Gene therapy is a new therapeutic modality that holds vast potential for the treatment of genetic disorders. Retroviruses are used as a vehicle for the transfer of genes into mammalian cells. The process of gene transfer has been shown to depend on the cell cycle status of target cells. We constructed a mathematical model that integrates the kinetics of gene transfer with cell cycle kinetics. We define three cell populations: uninfected cells, cells with the virus in their cytoplasm, but not integrated, and infected cells, in which the viral DNA has integrated in their genome. Our model predicts that the stability of the viral particles after internalization in the cellular cytoplasm, limits the process of gene transfer. Intracellular viral half-life also limits the usefulness of synchronization experiments, used to detect cell cycle dependence of the gene transfer process. We use the predictions of our model to propose a new experimental method for the detection of cell cycle dependence of retrovirus mediated gene transfer. It is based on the maturity distributions of the infected cells, and it is independent of viral intracellular stability. Despite the importance of the viral intracellular half-life this quantity still remains unknown. An extended version of the model is used to simulate a novel experimental method that measures the intracellular retroviral half-life. Analytical solutions of a simplified model confirm our numerical results and reveal the key dimensionless groups that characterize the process of gene transfer. Knowledge of the intracellular half-life of retroviral vectors is of particular importance for the design of new vectors, especially for slowly growing target cells, such as the stem cells of the hematopoietic system.

Entities:  

Mesh:

Year:  1996        PMID: 8917734     DOI: 10.1006/jtbi.1996.0140

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  7 in total

1.  Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.

Authors:  Pritha Agarwalla; Edikan A Ogunnaike; Sarah Ahn; Frances S Ligler; Gianpietro Dotti; Yevgeny Brudno
Journal:  Adv Healthc Mater       Date:  2020-06-11       Impact factor: 9.933

2.  Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours.

Authors:  S T Andreadis; D Brott; A O Fuller; B O Palsson
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Effect of serum on transfection by polyethylenimine/virus-like particle hybrid gene delivery vectors.

Authors:  David M Drake; Rahul K Keswani; Daniel W Pack
Journal:  Pharm Res       Date:  2010-08-21       Impact factor: 4.200

4.  A Moloney murine leukemia virus-based retroviral vector pseudotyped by the insect retroviral gypsy envelope can infect Drosophila cells.

Authors:  L Teysset; J C Burns; H Shike; B L Sullivan; A Bucheton; C Terzian
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection.

Authors:  S Andreadis; T Lavery; H E Davis; J M Le Doux; M L Yarmush; J R Morgan
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Improved retroviral suicide gene transfer in colon cancer cell lines after cell synchronization with methotrexate.

Authors:  Laetitia Finzi; Aurore Kraemer; Claude Capron; Severine Noullet; Diane Goere; Christophe Penna; Bernard Nordlinger; Josette Legagneux; Jean-Fançois Emile; Robert Malafosse
Journal:  J Exp Clin Cancer Res       Date:  2011-10-04

7.  Modeling of the HIV-1 Life Cycle in Productively Infected Cells to Predict Novel Therapeutic Targets.

Authors:  Olga Shcherbatova; Dmitry Grebennikov; Igor Sazonov; Andreas Meyerhans; Gennady Bocharov
Journal:  Pathogens       Date:  2020-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.